NASDAQ$TBPH
Theravance Biopharma Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Theravance Biopharma Inc Q1 fiscal 2026: $17.70B revenue, $4.9M net loss
for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 23, 2026. UPELRI, and the Company co-promotes the product under a profit and loss sharing arrangement ( 65 % to Viatris; 35 % to the Company). (SEC accession 0001104659-26-056760)
- Revenue: $17.70B
- Net loss: $4.9M
- Diluted EPS: $-0.10
- Operating income: $-9.5M
- UPELRI, and the Company co-promotes the product under a profit and loss sharing arrangement ( 65 % to Viatris; 35 % to the Company).
Headline financials
Revenue & EPS history
Theravance · Revenue · Quarterly
$17.7M
Revenue by segment
Theravance · $19.4K total across 1 segment · Q3 2022
- YUPELRI$19.4K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-0.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+0.7%
Avg return
30 days after
52%
25 / 48 earnings
Positive
+22.6%
Q3 2025
Best reaction
-20.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.5% | -2.8% | — | |
| Q4 2025 | +2.9% | +9.1% | +23.0% | |
| Q3 2025 | +22.6% | +15.3% | +17.2% | |
| Q1 2025 | -9.0% | -15.1% | +13.6% | |
| Q4 2024 | +2.1% | +0.2% | +1.7% | |
| Q3 2024 | +6.6% | +4.8% | +8.7% | |
| Q2 2024 | -18.8% | -20.5% | -16.6% | |
| Q1 2024 | +0.1% | -1.0% | -7.9% | |
| Q4 2023 | +7.9% | +5.1% | +0.3% | |
| Q3 2023 | +2.8% | +1.3% | +6.3% | |
| Q2 2023 | -2.1% | +0.2% | -4.0% | |
| Q1 2023 | +0.4% | -0.3% | -1.4% | |
| Q4 2022 | +9.4% | +2.0% | +8.6% | |
| Q3 2022 | +4.0% | +13.2% | +7.4% | |
| Q2 2022 | -5.4% | -2.6% | +1.4% | |
| Q1 2022 | -9.5% | -10.5% | -12.0% | |
| Q4 2021 | +6.3% | +7.8% | +4.0% | |
| Q3 2021 | +7.1% | +12.7% | -2.1% | |
| Q2 2021 | -5.9% | -5.9% | -36.4% | |
| Q1 2021 | -1.5% | -0.6% | -15.6% | |
| Q4 2020 | -3.3% | -8.4% | +10.7% | |
| Q3 2020 | -13.4% | -3.6% | -12.0% | |
| Q2 2020 | -11.9% | -15.8% | -15.8% | |
| Q1 2020 | -2.5% | +3.8% | -6.7% | |
| Q4 2019 | -10.5% | +0.6% | +0.7% | |
| Q3 2019 | +0.9% | +3.3% | +23.3% | |
| Q2 2019 | +6.4% | -0.1% | +10.8% | |
| Q1 2019 | -11.8% | -12.8% | -37.8% | |
| Q4 2018 | +1.0% | -0.5% | -7.0% | |
| Q3 2018 | -1.5% | +7.5% | +14.1% | |
| Q2 2018 | +17.3% | +20.3% | +21.0% | |
| Q1 2018 | +5.4% | +7.2% | +1.1% | |
| Q4 2017 | -8.4% | +0.7% | -15.7% | |
| Q3 2017 | -4.3% | -0.7% | -10.6% | |
| Q2 2017 | -20.0% | -19.3% | +3.8% | |
| Q1 2017 | +1.5% | -4.6% | -3.4% | |
| Q4 2016 | +1.0% | +5.9% | +22.2% | |
| Q3 2016 | +17.6% | +32.1% | +17.6% | |
| Q2 2016 | +3.0% | +6.2% | +15.6% | |
| Q1 2016 | +5.1% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | +3.0% | — | — | |
| Q4 2014 | -6.9% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -7.5% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro